



2024 Publications MSCA

1. [9-HODE associates with thalamic atrophy and predicts white matter damage in multiple sclerosis.](#) Fung WH, van Lingen MR, Broos JY, Lam KH, van Dam M, Fung WK, Noteboom S, Koubiyr I, de Vries HE, Jasperse B, Teunissen CE, Giera M, Killestein J, Hulst HE, Strijbis EMM, Schoonheim MM, Kooij G. Mult Scler Relat Disord. 2024 Dec;92:105946. doi: 10.1016/j.msard.2024.105946. Epub 2024 Oct 16. PMID: 39447246 Free article.
2. [Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations.](#) Coerver EM, Kaçar S, Ciccarelli O, Sormani MP, Barkhof F, Arnold DL, Schoonheim MM, Van Kempen ZL, Mostert J, Koch MW, Killestein J, Eshaghi A, Uitdehaag BM, Strijbis EM. Mult Scler. 2024 Sep;30(10):1296-1308. doi: 10.1177/13524585241272938. Epub 2024 Sep 8. PMID: 39245991 Free PMC article.
3. [Arachidonic acid-derived lipid mediators in multiple sclerosis pathogenesis: fueling or dampening disease progression?](#) Broos, J. Y., van der Burgt, R. T. M., Konings, J., Rijnsburger, M., Werz, O., de Vries, H. E., Giera, M. & Kooij, G., Dec 2024, In: Journal of neuroinflammation. 21, 1, p. 21 21. Research output: Contribution to journal > Review article > Academic > peer-review
4. [Atrophy Patterns in Patients With Multiple Sclerosis With Cognitive Impairment, Fatigue, and Mood Disorders.](#) Rimkus CM, Nucci MP, Avolio IB, Apóstolos-Pereira SL, Callegaro D, Wagner MB, Schoonheim MM, Barkhof F, Leite CC. Neurology. 2024 Dec 24;103(12):e210080. doi: 10.1212/WNL.0000000000210080. Epub 2024 Nov 21. PMID: 39571119
5. [Brain reserve and physical disability in secondary progressive multiple sclerosis.](#) John N, Li Y, De Angelis F, Stutters J, Prados Carrasco F, Eshaghi A, Doshi A, Calvi A, Williams T, Plantone D, Phan T, Barkhof F, Chataway J; MS-SMART Investigators; Ourselin S, Braisher M, Beyene T, Bassan V, Zapata A, Chandran S, Connick P, Lyle D, Cameron J, Mollison D, Colville S, Dhillon B, Ross M, Cranswick G, Walker A, Smith L, Giovannoni G, Gnanapavan S, Nicholas R, Rashid W, Aram J, Ford H, Pavitt SH, Overell J, Young C, Arndt H, Duddy M, Guadagno J, Evangelou N, Craner M, Palace J, Hobart J, Sharrack B, Paling D, Hawkins C, Kalra S, McLean B, Stallard N, Bastow R. BMJ Neurol Open. 2024 Sep 7;6(2):e000670. doi: 10.1136/bmjno-2024-000670. eCollection 2024. PMID: 39262426 Free PMC article.
6. [Physical Activity Levels, Correlates, and All-Cause Mortality Risk in People Living With Different Health Conditions.](#) Marks-Vieeen JM, Uijtdewilligen L, Motazed E, Stijnman DPM, van den Akker-Scheek I, Bouma AJ, Buffart LM, de Groot V, de Hollander E, Jelsma JGM, de Jong J, van Keeken HG, Krops LA, van der Leeden M, Loer SA, van Mechelen W, van Nassau F, Nauta J, Verhagen E, Wendel-Vos W, van der Woude LHV, Zwerver J, Dekker R, van der Ploeg HP. Physical Activity Levels, Correlates, and All-. J Phys Act Health. 2024 Feb 24;21(4):394-404. doi: 10.1123/jpah.2023-0387. PMID: 38402878.
7. [Changing multiple-sclerosis-induced thoughts and behaviours.](#) Beckerman H, de Groot V. Lancet Neurol. 2024 Nov;23(11):1067-1068. doi: 10.1016/S1474-4422(24)00401-0. PMID: 39424547 No abstract available.
8. [Clinical risk stratification: Development and validation of the DAAE score, a tool for estimating patient risk of transition to secondary progressive multiple sclerosis.](#) Fuchs TA, Zivadinov R, Pryshchepova T, Weinstock-Guttman B, Dwyer MG, Benedict RHB, Bergsland N, Jakimovski D, Uher T, Jelgerhuis JR, Barkhof F, Uitdehaag BMJ, Killestein J, Strijbis EMM, Schoonheim MM. Mult Scler Relat Disord. 2024 Sep;89:105755. doi: 10.1016/j.msard.2024.105755. Epub 2024 Jul 6. PMID: 39018643 Free article.

9. [Cognitive progression independent of relapse in multiple sclerosis.](#) Fuchs TA, Schoonheim MM, Zivadinov R, Dwyer MG, Colato E, Weinstock Z, Weinstock-Guttman B, Strijbis EM, Benedict RH. *Mult Scler.* 2024 Oct;30(11-12):1468-1478. doi: 10.1177/13524585241256540. Epub 2024 Aug 28.PMID: 39193699
10. [Conservation of structural brain connectivity in people with multiple sclerosis.](#) Martí-Juan G, Sastre-Garriga J, Vidal-Jordana A, Llufríu S, Martínez-Heras E, Groppa S, González-Escamilla G, Rocca MA, Filippi M, Høgestøl EA, Harbo HF, Foster MA, Collorone S, Toosy AT, Schoonheim MM, Strijbis E, Pontillo G, Petracca M, Deco G, Rovira À, Pareto D. *Netw Neurosci.* 2024 Dec 10;8(4):1545-1562. doi: 10.1162/netn_a_00404. eCollection 2024.PMID: 39735510 Free PMC article.
11. [Cortical lesions impact cognitive decline in multiple sclerosis via volume loss of nonlesional cortex.](#) Krijnen EA, van Dam M, Bajrami A, Bouman PM, Noteboom S, Barkhof F, Uitdehaag BMJ, Steenwijk MD, Klawiter EC, Koubiyr I, Schoonheim MM. *Ann Clin Transl Neurol.* 2024 Dec 27. doi: 10.1002/acn3.52261. Online ahead of print.PMID: 39729590 Free article.
12. [Current and future role of MRI in the diagnosis and prognosis of multiple sclerosis.](#) Rocca MA, Preziosa P, Barkhof F, Brownlee W, Calabrese M, De Stefano N, Granziera C, Ropele S, Toosy AT, Vidal-Jordana À, Di Filippo M, Filippi M. *Lancet Reg Health Eur.* 2024 Aug 22;44:100978. doi: 10.1016/j.lanepe.2024.100978. eCollection 2024 Sep.PMID: 39444702 Free PMC article. Review.
13. [Demyelinating Diseases of the CNS \(Brain and Spine\).](#) Barkhof F, Koeller KK. 2024 Feb 11. In: Hodler J, Kubik-Huch RA, Roos JE, editors. *Diseases of the Brain, Head and Neck, Spine 2024-2027: Diagnostic Imaging* [Internet]. Cham (CH): Springer; 2024. Chapter 13.PMID: 39495887 Free Books & Documents. Review.
14. [Diagnostic Performance of Cortical Lesions and the Central Vein Sign in Multiple Sclerosis.](#) Cagol A, Cortese R, Barakovic M, Schaedelin S, Ruberte E, Absinta M, Barkhof F, Calabrese M, Castellaro M, Ciccarelli O, Cocozza S, De Stefano N, Enzinger C, Filippi M, Jurynczyk M, Maggi P, Mahmoudi N, Messina S, Montalban X, Palace J, Pontillo G, Pröbstel AK, Rocca MA, Ropele S, Rovira À, Schoonheim MM, Sowa P, Strijbis E, Wattjes MP, Sormani MP, Kappos L, Granziera C; MAGNIMS Study Group. *JAMA Neurol.* 2024 Feb 1;81(2):143-153. doi: 10.1001/jamaneurol.2023.4737.PMID: 38079177 Free PMC article.
15. [Digital outcome measures are associated with brain atrophy in patients with multiple sclerosis.](#) Molenaar PCG, Noteboom S, van Nderpelt DR, Krijnen EA, Jelgerhuis JR, Lam KH, Duijff-van de Woestijne GB, Meijer KA, van Oirschot P, de Jong BA, Brouwer I, Jasperse B, de Groot V, Uitdehaag BMJ, Schoonheim MM, Strijbis EMM, Killestein J. *J Neurol.* 2024 Sep;271(9):5958-5968. doi: 10.1007/s00415-024-12516-9. Epub 2024 Jul 15.PMID: 39008036 Free PMC article.
16. [Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial.](#) Coerver EME, Fung WH, de Beukelaar J, Bouvy WH, Canta LR, Gerlach OHH, Hoitsma E, Hoogervorst ELJ, de Jong BA, Kalkers NF, van Kempen ZLE, Lövenich H, van Munster CEP, van Oosten BW, Smolders J, Vennegoor A, Zeinstra EMPE, Barrantes-Cepas M, Kooij G, Schoonheim MM, Lissenberg-Witte BI, Teunissen CE, Moraal B, Barkhof F, Uitdehaag BMJ, Mostert J, Killestein J, Strijbis EMM. *JAMA Neurol.* 2024 Dec 9. doi: 10.1001/jamaneurol.2024.4164. Online ahead of print.PMID: 39652340
17. [Disease progression in the first 5 years of treatment in multiple sclerosis: Predictive value of early brain and lesion volume changes.](#) Mattiesing RM, Kramer E, Strijbis EM, Brouwer I, van Schijndel RA, Gentile G, Battaglini M, De Stefano N, Uitdehaag BM, Barkhof F, Vrenken H, Schoonheim MM. *Mult Scler.* 2024 Jan;30(1):44-54. doi: 10.1177/13524585231212879. Epub 2023 Nov 29.PMID: 38018502 Free PMC article.

18. [Disentangling Neurodegeneration From Aging in Multiple Sclerosis Using Deep Learning: The Brain-Predicted Disease Duration Gap.](#) Pontillo G, Prados F, Colman J, Kanber B, Abdel-Mannan O, Al-Araji S, Bellenberg B, Bianchi A, Bisecco A, Brownlee WJ, Brunetti A, Cagol A, Calabrese M, Castellaro M, Christensen R, Cocozza S, Colato E, Collorone S, Cortese R, De Stefano N, Enzinger C, Filippi M, Foster MA, Gallo A, Gasperini C, Gonzalez-Escamilla G, Granziera C, Groppa S, Hacohen Y, Harbo HFF, He A, Hogestol EA, Kuhle J, Llufríu S, Lukas C, Martinez-Heras E, Messina S, Moccia M, Mohamud S, Nistri R, Nygaard GO, Palace J, Petracca M, Pinter D, Rocca MA, Rovira A, Ruggieri S, Sastre-Garriga J, Strijbis EM, Toosy AT, Uher T, Valsasina P, Vaneckova M, Vrenken H, Wingrove J, Yam C, Schoonheim MM, Ciccarelli O, Cole JH, Barkhof F; MAGNIMS study group. *Neurology*. 2024 Nov 26;103(10):e209976. doi: 10.1212/WNL.000000000209976. Epub 2024 Nov 4. PMID: 39496109 Free PMC article.
19. [Don't be late! Postponing cognitive decline and preventing early unemployment in people with multiple sclerosis: a study protocol.](#) Aarts J, Saddal SRD, Bosmans JE, de Groot V, de Jong BA, Klein M, Ruitenbergh MFL, Schaafsma FG, Schippers ECF, Schoonheim MM, Uitdehaag BMJ, van der Veen S, Waskowiak PT, Widdershoven GAM, van der Hiele K, Hulst HE; Don't be late! consortium. *BMC Neurol*. 2024 Jan 15;24(1):28. doi: 10.1186/s12883-023-03513-y. PMID: 38225561 Free PMC article.
20. [Don't be late! Timely identification of cognitive impairment in people with multiple sclerosis: a study protocol.](#) Waskowiak PT, de Jong BA, Uitdehaag BMJ, Saddal SRD, Aarts J, Roovers AAM, van Oirschot P, de Groot V, Schaafsma FG, van der Hiele K, Ruitenbergh MFL, Schoonheim MM, Widdershoven GAM, van der Veen S, Schippers ECF, Klein M, Hulst HE; Don't be late! Consortium. *BMC Neurol*. 2024 Jan 13;24(1):26. doi: 10.1186/s12883-023-03495-x. PMID: 38218777 Free PMC article.
21. [Effectiveness of a blended booster programme for the long-term outcome of cognitive behavioural therapy for MS-related fatigue: A randomized controlled trial.](#) de Gier M, Beckerman H, Twisk JW, Knoop H, de Groot V. *Mult Scler*. 2024 Jan;30(1):71-79. doi: 10.1177/13524585231213258. Epub 2023 Nov 29. PMID: 38018811 Free PMC article. Clinical Trial.
22. [Eigenvector Centrality Mapping Reveals Volatility of Functional Brain Dynamics in Anti-NMDA Receptor Encephalitis.](#) Hartung TJ, von Schwanenflug N, Krohn S, Broeders TAA, Prüss H, Schoonheim MM, Finke C. *Biol Psychiatry Cogn Neurosci Neuroimaging*. 2024 Nov;9(11):1222-1229. doi: 10.1016/j.bpsc.2024.07.021. Epub 2024 Jul 27. PMID: 39074556 Free article.
23. [Endothelial cells and macrophages as allies in the healthy and diseased brain.](#) Denes A, Hansen CE, Oezorhan U, Figuerola S, de Vries HE, Sorokin L, Planas AM, Engelhardt B, Schwaninger M. *Acta Neuropathol*. 2024 Feb 12;147(1):38. doi: 10.1007/s00401-024-02695-0. PMID: 38347307 Free PMC article. Review.
24. [Energy Associated With Dynamic Network Changes in Patients With Multiple Sclerosis and Cognitive Impairment.](#) Broeders TAA, van Dam M, Pontillo G, Rauh V, Douw L, van der Werf YD, Killestein J, Barkhof F, Vinkers CH, Schoonheim MM. *Neurology*. 2024 Nov 12;103(9):e209952. doi: 10.1212/WNL.000000000209952. Epub 2024 Oct 11. PMID: 39393029 Free PMC article.
25. [Estimated Brain Age in Healthy Aging and Across Multiple Neurological Disorders.](#) Chai L, Sun J, Zhuo Z, Wei R, Xu X, Duan Y, Tian D, Bai Y, Zhang N, Li H, Li Y, Li Y, Zhou F, Xu J, Cole JH, Barkhof F, Zhang J, Zheng H, Liu Y. *J Magn Reson Imaging*. 2024 Nov 26. doi: 10.1002/jmri.29667. Online ahead of print. PMID: 39588683
26. [Evaluating multiple sclerosis severity loci 30 years after a clinically isolated syndrome.](#) Sahi N, Haider L, Chung K, Prados Carrasco F, Kanber B, Samson R, Thompson AJ, Trip SA, Brownlee W, Ciccarelli O, Barkhof F, Tur C, Houlden H, Chard D. *Brain Commun*. 2024 Dec 5;6(6):fcae443. doi: 10.1093/braincomms/fcae443. eCollection 2024. PMID: 39670111 Free PMC article.
27. [Evaluation of machine learning-based classification of clinical impairment and prediction of clinical worsening in multiple sclerosis.](#) Noteboom S, Seiler M, Chien C, Rane RP, Barkhof F, Strijbis EMM, Paul F, Schoonheim MM, Ritter K. *J Neurol*. 2024 Aug;271(8):5577-5589. doi: 10.1007/s00415-024-12507-w. Epub 2024 Jun 23. PMID: 38909341 Free PMC article.

28. [Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis.](#) Toorop AA, Noteboom S, Steenwijk MD, Gravendeel JW, Jasperse B, Barkhof F, Strijbis EM, Rispens T, Schoonheim MM, van Kempen ZL, Killestein J. *Mult Scler.* 2024 Feb;30(2):266-271. doi: 10.1177/13524585231225855. Epub 2024 Jan 18. PMID: 38235514 Free PMC article.
29. [Exploring Vitreous Haze as a Potential Biomarker for Accelerated Glymphatic Outflow and Neurodegeneration in Multiple Sclerosis: A Cross-Sectional Study](#) Kaçar, S., Coric, D., Ometto, G., Montesano, G., Denniston, A. K., Keane, P. A., Uitdehaag, B. M. J., Crabb, D. P., Schoonheim, M. M., Petzold, A. & Strijbis, E. M. M., 1 Jan 2024, In: *Brain sciences.* 14, 1, 36. Research output: Contribution to journal › Article › Academic › peer-review
30. [Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease](#), Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis. Cortese R, Battaglini M, Prados F, Gentile G, Luchetti L, Bianchi A, Haider L, Jacob A, Palace J, Messina S, Paul F, Marignier R, Durand-Dubief F, de Medeiros Rimkus C, Apostolos Pereira SL, Sato DK, Filippi M, Rocca MA, Cacciaguerra L, Rovira À, Sastre-Garriga J, Arrambide G, Liu Y, Duan Y, Gasperini C, Tortorella C, Ruggieri S, Amato MP, Ulivelli M, Groppa S, Grothe M, Llüfriu S, Sepulveda M, Lukas C, Bellenberg B, Schneider R, Sowa P, Celius EG, Pröbstel AK, Granziera C, Yaldizli Ö, Müller J, Stankoff B, Bodini B, Barkhof F, Ciccarelli O, De Stefano N; MAGNIMS Study Group. *Ann Neurol.* 2024 Aug;96(2):276-288. doi: 10.1002/ana.26951. Epub 2024 May 23. PMID: 38780377
31. [Higher-order functional connectivity analysis of resting-state functional magnetic resonance imaging data using multivariate cumulants.](#) Hindriks R, Broeders TAA, Schoonheim MM, Douw L, Santos F, van Wieringen W, Tewarie PKB. *Hum Brain Mapp.* 2024 Apr;45(5):e26663. doi: 10.1002/hbm.26663. PMID: 38520377 Free PMC article.
32. [Human post-mortem organotypic brain slice cultures: a tool to study pathomechanisms and test therapies.](#) Plug BC, Revers IM, Breur M, González GM, Timmerman JA, Meijns NRC, Hamberg D, Wagendorp J, Nutma E, Wolf NI, Luchicchi A, Mansvelter HD, van Til NP, van der Knaap MS, Bugiani M. *Acta Neuropathol Commun.* 2024 May 31;12(1):83. doi: 10.1186/s40478-024-01784-1. PMID: 38822428 Free PMC article.
33. [Identifying and understanding cognitive profiles in multiple sclerosis: a role for visuospatial memory functioning.](#) van Dam M, Krijnen EA, Nauta IM, Fuchs TA, de Jong BA, Klein M, van der Hiele K, Schoonheim MM, Hulst HE. *J Neurol.* 2024 May;271(5):2195-2206. doi: 10.1007/s00415-024-12227-1. Epub 2024 Feb 26. PMID: 38409536 Free PMC article.
34. [Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic.](#) van Lierop ZY, Wessels MH, Lekranty WM, Moraal B, Hof SN, Hogenboom L, de Jong BA, Meijs N, Mensing LA, van Oosten BW, Sol N, van Kempen ZL, Vermunt L, Willems MJ, Strijbis EM, Uitdehaag BM, Killestein J, Teunissen CE. *Mult Scler.* 2024 Nov;30(13):1620-1629. doi: 10.1177/13524585241277044. Epub 2024 Oct 17. PMID: 39420574 Free PMC article.
35. [Improving criteria for dissemination in space in multiple sclerosis by including additional regions.](#) Foster MA, Pontillo G, Davagnanam I, Collorone S, Prados F, Kanber B, Yiannakas MC, Ogunbowale L, Burke A, Gandini Wheeler-Kingshott CAM, Ciccarelli O, Brownlee W, Barkhof F, Toosy AT. *Ann Clin Transl Neurol.* 2024 Oct;11(10):2572-2582. doi: 10.1002/acn3.52170. Epub 2024 Jul 30. PMID: 39078773 Free PMC article.
36. [Improving explanation of motor disability with diffusion-based graph metrics at onset of the first demyelinating event.](#) Foster MA, Prados F, Collorone S, Kanber B, Cawley N, Davagnanam I, Yiannakas MC, Ogunbowale L, Burke A, Barkhof F, Wheeler-Kingshott CAG, Ciccarelli O, Brownlee W, Toosy AT. *Mult Scler.* 2024 Jun;30(7):800-811. doi: 10.1177/13524585241247785. Epub 2024 May 15. PMID: 38751221 Free PMC article.

37. [Inflammation-induced TRPV4 channels exacerbate blood-brain barrier dysfunction in multiple sclerosis.](#) Hansen CE, Kamermans A, Mol K, Berve K, Rodriguez-Mogeda C, Fung WK, van Het Hof B, Fontijn RD, van der Pol SMA, Michalick L, Kuebler WM, Kenkhuis B, van Roon-Mom W, Liedtke W, Engelhardt B, Kooij G, Witte ME, de Vries HE. *J Neuroinflammation*. 2024 Mar 23;21(1):72. doi: 10.1186/s12974-024-03069-9. PMID: 38521959 Free PMC article.
38. [Inhibition of constitutive activity of the atypical chemokine receptor ACKR3 by the small-molecule inverse agonist VUF16840.](#) Reggie Bosma, Desislava Nesheva, Merel Rijnsburger, Rick Riemens, Justyna M. Adamska, Max Meyrath, Simon Mobach, C. Maurice Buzink, Iwan J. P. de Esch, Martyna Szpakowska, Maikel Wijtmans, Andy Chevigne, Henry F. Vischer, Rob Leurs. doi: <https://doi.org/10.1101/2024.12.30.630720>
39. [Intrathecal IgG and IgM synthesis correlates with neurodegeneration markers and corresponds to meningeal B cell presence in MS.](#) Rodriguez-Mogeda C, van Gool MM, van der Mast R, Nijland R, Keasberry Z, van de Bovekamp L, van Delft MA, Picon C, Reynolds R, Killestein J, Teunissen CE, de Vries HE, van Egmond M, Witte ME. *Sci Rep*. 2024 Oct 26;14(1):25540. doi: 10.1038/s41598-024-76969-8. PMID: 39462090 Free PMC article.
40. [Intrinsic and extrinsic contributors to subregional thalamic volume loss in multiple sclerosis.](#) Krijnen EA, Salim Karam E, Russo AW, Lee H, Chiang FL, Schoonheim MM, Huang SY, Klawiter EC. *Ann Clin Transl Neurol*. 2024 Jun;11(6):1405-1419. doi: 10.1002/acn3.52026. Epub 2024 May 9. PMID: 38725151 Free PMC article
41. [Investigating the relationship between thalamic iron concentration and disease severity in secondary progressive multiple sclerosis using quantitative susceptibility mapping: Cross-sectional analysis from the MS-STAT2 randomised controlled trial.](#) Williams T, John N, Calvi A, Bianchi A, De Angelis F, Doshi A, Wright S, Shatila M, Yiannakas MC, Chowdhury F, Stutters J, Ricciardi A, Prados F, MacManus D, Grussu F, Karsa A, Samson B, Battiston M, Gandini Wheeler-Kingshott CAM, Shmueli K, Ciccarelli O, Barkhof F, Chataway J; UCL MS-STAT2 investigators. *Neuroimage Rep*. 2024 Sep;4(3):100216. doi: 10.1016/j.ynirp.2024.100216. PMID: 39328985 Free PMC article.
42. [Isolated cognitive impairment in people with multiple sclerosis: frequency, MRI patterns and its development over time.](#) Bouman PM, van Dam MA, Jonkman LE, Steenwijk MD, Schoonheim MM, Geurts JGG, Hulst HE. *J Neurol*. 2024 May;271(5):2159-2168. doi: 10.1007/s00415-024-12185-8. Epub 2024 Jan 30. PMID: 38286843 Free PMC article.
43. [Longitudinal fibre-specific white matter damage predicts cognitive decline in multiple sclerosis.](#) Koubiyr I, Krijnen EA, Eijlers AJC, Dekker I, Hulst HE, Uitdehaag BMJ, Barkhof F, Geurts JGG, Schoonheim MM. *Brain Commun*. 2024 Jan 27;6(1):fcae018. doi: 10.1093/braincomms/fcae018. eCollection 2024. PMID: 38344654 Free PMC article.
44. [Longitudinal Metabolite Changes in Progressive Multiple Sclerosis: A Study of 3 Potential Neuroprotective Treatments.](#) John NA, Solanky BS, De Angelis F, Parker RA, Weir CJ, Stutters J, Carrasco FP, Schneider T, Doshi A, Calvi A, Williams T, Plantone D, Monteverdi A, MacManus D, Marshall I, Barkhof F, Gandini Wheeler-Kingshott CAM, Chataway J; MS-SMART Investigators. *J Magn Reson Imaging*. 2024 Jun;59(6):2192-2201. doi: 10.1002/jmri.29017. Epub 2023 Oct 3. PMID: 37787109 Clinical Trial.
45. [Longitudinal network-based brain grey matter MRI measures are clinically relevant and sensitive to treatment effects in multiple sclerosis.](#) Colato E, Stutters J, Narayanan S, Arnold DL, Chataway J, Gandini Wheeler-Kingshott CAM, Barkhof F, Ciccarelli O, Eshaghi A, Chard DT. *Brain Commun*. 2024 Jul 29;6(4):fcae234. doi: 10.1093/braincomms/fcae234. eCollection 2024. PMID: 39077376 Free PMC article.
46. [Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial.](#) Kappos L, Edan G, Freedman MS, Hartung HP, Montalbán X, Barkhof F, Koelbach R, MacManus DG, Wicklein EM; BENEFIT and BENEFIT 15 Study Groups. *J Neurol*. 2024 Jul;271(7):4599-4609. doi: 10.1007/s00415-024-12417-x. Epub 2024 May 10. PMID: 38730097 Free PMC article. Clinical Trial.

47. [Long-term neuroprotective effects of natalizumab and fingolimod in multiple sclerosis: Evidence from real-world clinical data.](#) Noteboom S, Strijbis EMM, Coerver EME, Colato E, van Kempen ZLE, Jasperse B, Vrenken H, Killestein J, Schoonheim MM, Steenwijk MD. *Mult Scler Relat Disord*. 2024 Jul;87:105670. doi: 10.1016/j.msard.2024.105670. Epub 2024 May 10.PMID: 38772150 Free article.
48. [Micro-diffusely abnormal white matter: An early multiple sclerosis lesion phase with intensified myelin blistering.](#) Luchicchi A, Muñoz-Gonzalez G, Halperin ST, Strijbis E, van Dijk LHM, Foutiadou C, Uriac F, Bouman PM, Schouten MAN, Plemel J, 't Hart BA, Geurts JJG, Schenk GJ. *Ann Clin Transl Neurol*. 2024 Apr;11(4):973-988. doi: 10.1002/acn3.52015. Epub 2024 Feb 29.PMID: 38425098 Free PMC article
49. [Mood Associated With Health- and Social Care-Related Quality of Life in Patients With Advanced Multiple Sclerosis.](#) Ouwerkerk M, Rietberg MB, van der Linden MMW, Uitdehaag BMJ, van Wegen EEH, de Groot V. *Int J MS Care*. 2024 Aug 1;26(Q3):199-206. doi: 10.7224/1537-2073.2023-060. eCollection 2024 May.PMID: 39091383 Free PMC article.
50. [Multimodal MRI study on the relation between WM integrity and connected GM atrophy and its effect on disability in early multiple sclerosis.](#) Weeda MM, van Nederpelt DR, Twisk JWR, Brouwer I, Kuijer JPA, van Dam M, Hulst HE, Killestein J, Barkhof F, Vrenken H, Pouwels PJW. *J Neurol*. 2024 Jan;271(1):355-373. doi: 10.1007/s00415-023-11937-2. Epub 2023 Sep 17.PMID: 37716917 Free PMC article.
51. [Multiple sclerosis can be diagnosed solely with dissemination in space: Yes.](#) Toosy AT, Barkhof F. *Mult Scler*. 2024 May;30(6):637-639. doi: 10.1177/13524585241245313. Epub 2024 Apr 14.PMID: 38616522 Free PMC article. No abstract available.
52. [Network Analysis in Multiple Sclerosis and Related Disorders.](#) Pontillo G, Cepas MB, Broeders TAA, Koubiyr I, Schoonheim MM. *Neuroimaging Clin N Am*. 2024 Aug;34(3):375-384. doi: 10.1016/j.nic.2024.03.008. Epub 2024 Apr 25.PMID: 38942522 Review.
53. [Neurofilament light protein as a biomarker for spinal muscular atrophy: A review and reference ranges](#) Bayoumy, S., Verberk, I. M. W., Vermunt, L., Willemse, E., den Dulk, B., van der Ploeg, A. T., Pajkrt, D., Nitz, E., van den Hout, J. M. P., van der Post, J., Wolf, N. I., Beerepoot, S., Groen, E. J. N., Tüngler, V. & Teunissen, C. E., 1 Jun 2024, In: *Clinical chemistry and laboratory medicine*. 62, 7, p. 1252-1265 14 p.
54. [Neurofilaments as biomarkers in neurological disorders – towards clinical application](#) Khalil, M., Teunissen, C. E., Lehmann, S., Otto, M., Piehl, F., Ziemssen, T., Bittner, S., Sormani, M. P., Gatringer, T., Abu-Rumeileh, S., Thebault, S., Abdelhak, A., Green, A., Benkert, P., Kappos, L., Comabella, M., Tumani, H., Freedman, M. S., Petzold, A., Blennow, K., & 3 others, 1 May 2024, In: *Nature Reviews. Neurology*. 20, 5, p. 269-287 19 p. Research output: Contribution to journal › Review article › Academic › peer-review
55. [Neurophysiological brain function predicts response to cognitive rehabilitation and mindfulness in multiple sclerosis: a randomized trial.](#) Nauta IM, Kessels RPC, Bertens D, Stam CJ, Strijbis EEM, Hillebrand A, Fasotti L, Uitdehaag BMJ, Hulst HE, Speckens AEM, Schoonheim MM, de Jong BA. *J Neurol*. 2024 Apr;271(4):1649-1662. doi: 10.1007/s00415-024-12183-w. Epub 2024 Jan 26.PMID: 38278979 Free PMC article. Clinical Trial.
56. [Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.](#) Kappos L, Traboulsee A, Li DKB, Bar-Or A, Barkhof F, Montalban X, Leppert D, Baldinotti A, Schneble HM, Koendgen H, Sauter A, Wang Q, Hauser SL. *J Neurol*. 2024 Feb;271(2):642-657. doi: 10.1007/s00415-023-11943-4. Epub 2023 Oct 31.PMID: 37906326 Free PMC article.

57. [Optic chiasm involvement in multiple sclerosis, aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein-associated disease.](#) Bianchi A, Cortese R, Prados F, Tur C, Kanber B, Yiannakas MC, Samson R, De Angelis F, Magnollay L, Jacob A, Brownlee W, Trip A, Nicholas R, Hacohen Y, Barkhof F, Ciccarelli O, Toosy AT. *Mult Scler.* 2024 May;30(6):674-686. doi: 10.1177/13524585241240420. Epub
58. [Optical coherence tomography in secondary progressive multiple sclerosis: cross-sectional and longitudinal exploratory analysis from the MS-SMART randomised controlled trial.](#) De Angelis F, Cameron JR, Eshaghi A, Parker R, Connick P, Stutters J, Plantone D, Doshi A, John N, Williams T, Calvi A, MacManus D, Barkhof F, Chandran S, Weir CJ, Toosy A, Chataway J; MS-SMART trial investigators. *J Neurol Neurosurg Psychiatry.* 2024 Dec 18;jnnp-2024-334801. doi: 10.1136/jnnp-2024-334801. Online ahead of print.PMID: 39694820 Free article.
59. [Perceived and physiological strains of societal participation in people with multiple sclerosis: a real-time assessment study.](#) Gravesteijn AS, Ouwerkerk M, Eijssen ICJM, Beckerman H, De Groot V. *J Rehabil Med.* 2024 Jun 24;56:jrm40838. doi: 10.2340/jrm.v56.40838.PMID: 38910543 Free PMC article.
60. [Prognostic value of single-subject grey matter networks in early multiple sclerosis.](#) Fleischer V, Gonzalez-Escamilla G, Pareto D, Rovira A, Sastre-Garriga J, Sowa P, Høgestøl EA, Harbo HF, Bellenberg B, Lukas C, Ruggieri S, Gasperini C, Uher T, Vaneckova M, Bittner S, Othman AE, Collorone S, Toosy AT, Meuth SG, Zipp F, Barkhof F, Ciccarelli O, Groppa S. *Brain.* 2024 Jan 4;147(1):135-146. doi: 10.1093/brain/awad288.PMID: 37642541 Free PMC article.
61. [Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis \(NEXT-MS\).](#) Toorop AA, van Lierop ZY, Gelissen LM, Hoitsma E, Zeinstra EM, van Rooij LC, van Munster CE, Vennegoor A, Mostert JP, Wokke BH, Kalkers NF, Hoogervorst EL, van Eijk JJ, Roosendaal CM, Kragt JJ, Eurelings M, van Genugten J, Nielsen J, Sinnige L, Kloosterziel ME, Arnoldus EP, van Dijk GW, Bouvy WH, Wessels MH, Boonkamp L, Strijbis EM, van Oosten BW, De Jong BA, Lissenberg-Witte BI, Barkhof F, Moraal B, Teunissen CE, Rispens T, Uitdehaag BM, Killestein J, van Kempen ZL. *J Neurol Neurosurg Psychiatry.* 2024 Apr 12;95(5):392-400. doi: 10.1136/jnnp-2023-332119.PMID: 37963723 Clinical Trial.
62. [Proteomics Analysis Moves the Needle by Generating Clinical Diagnostic Markers](#) Teunissen, C. E., 1 May 2024, In: *Neurology(R) neuroimmunology & neuroinflammation.* 11, 3, p. e200256 Research output: Contribution to journal › Editorial › Academic › peer-review
63. [Recent Advances in Neuroimaging of Multiple Sclerosis and Related Demyelinating Disorders.](#) Barkhof F, Liu Y. *Neuroimaging Clin N Am.* 2024 Aug;34(3):xv-xvi. doi: 10.1016/j.nic.2024.04.001. Epub 2024 Apr 30.PMID: 38942530 No abstract available.
64. [Relative aerobic load of walking in people with multiple sclerosis.](#) Gravesteijn AS, Timmermans ST, Aarts J, Hulst HE, De Jong BA, Beckerman H, De Groot V. *J Rehabil Med.* 2024 Feb 14;56:jrm13352. doi: 10.2340/jrm.v56.13352.PMID: 38353255 Free PMC article.
65. [Scanner-specific optimisation of automated lesion segmentation in MS.](#) van Nederpelt DR, Pontillo G, Barrantes-Cepas M, Brouwer I, Strijbis EMM, Schoonheim MM, Moraal B, Jasperse B, Mutsaerts HMM, Killestein J, Barkhof F, Kuijer JPA, Vrenken H. *Neuroimage Clin.* 2024;44:103680. doi: 10.1016/j.nicl.2024.103680. Epub 2024 Oct 2.PMID: 39378750 Free PMC article.
66. [‘So Let’s Go On Like This?’-Shared Decision-Making and the Use of Outcome Information in Routine Care Management for People With Multiple Sclerosis.](#) Damman OC, Murugesu L, de Groot V, de Jong BA. *Health Expect.* 2024;27(5):e70009. doi:10.1111/hex.70009
67. [Spatially resolved gene signatures of white matter lesion progression in multiple sclerosis.](#) Alsema AM, Wijering MHC, Miedema A, Kotah JM, Koster M, Rijnsburger M, van Weering HRJ, de Vries HE, Baron W, Kooistra SM, Eggen BJL. *Nat Neurosci.* 2024 Dec;27(12):2341-2353. doi: 10.1038/s41593-024-01765-6. Epub 2024 Nov 5.PMID: 39501035

68. [Spinal Cord Imaging in Multiple Sclerosis and Related Disorders.](#) Jasperse B. *Neuroimaging Clin N Am.* 2024 Aug;34(3):385-398. doi: 10.1016/j.nic.2024.03.011. Epub 2024 May 9. PMID: 38942523 Review.
69. [Subtypes and location of \(juxta\)cortical lesions relate to cognitive dysfunction in people with multiple sclerosis.](#) Krijnen EA, Kouwenhoven RM, Noteboom S, Barkhof F, Uitdehaag BM, Klawiter EC, Steenwijk MD, Schoonheim MM, Koubiyr I. *Mult Scler.* 2024 Oct;30(11-12):1556-1560. doi: 10.1177/13524585241260968. Epub 2024 Jun 13. PMID: 38872276
70. [Tension at the gate: sensing mechanical forces at the blood-brain barrier in health and disease.](#) Hansen CE, Hollaus D, Kamermans A, de Vries HE. *J Neuroinflammation.* 2024 Dec 18;21(1):325. doi: 10.1186/s12974-024-03321-2. PMID: 39696463 Free PMC article. Review.
71. [Thalamic atrophy and dysconnectivity are associated with cognitive impairment in a multi-center, clinical routine, real-word study of people with relapsing-remitting multiple sclerosis.](#) Zivadinov R, Bergsland N, Jakimovski D, Weinstock-Guttman B, Loreface L, Schoonheim MM, Morrow SA, Ann Picone M, Pardo G, Zarif M, Gudesblatt M, Nicholas JA, Smith A, Hunter S, Newman S, AbdelRazek MA, Hoti I, Riolo J, Silva D, Fuchs TA, Dwyer MG, Hb Benedict R. *Neuroimage Clin.* 2024;42:103609. doi: 10.1016/j.nicl.2024.103609. Epub 2024 Apr 27. PMID: 38718640 Free PMC article.
72. [The cognitive relevance of non-lesional damage to cortical networks in people with multiple sclerosis.](#) Krijnen EA, Broeders TAA, Noteboom S, van Dam M, Bajrami A, Bouman PM, Barkhof F, Uitdehaag BMJ, Klawiter EC, Koubiyr I, Schoonheim MM. *J Neurol.* 2024 Jun;271(6):3203-3214. doi: 10.1007/s00415-024-12240-4. Epub 2024 Mar 5. PMID: 38441612 Free PMC article.
73. [The evolving contribution of MRI measures towards the prediction of secondary progressive multiple sclerosis.](#) Ananthavarathan P, Sahi N, Chung K, Haider L, Prados F, Trip SA, Ciccarella O, Barkhof F, Tur C, Chard DT. *J Neurol Neurosurg Psychiatry.* 2024 Jul 22:jnnp-2024-333917. doi: 10.1136/jnnp-2024-333917. Online ahead of print. PMID: 39038948
74. [The impact of image contrast, resolution and reader expertise on black hole identification in Multiple Sclerosis.](#) Tranfa M, Scaravilli A, Pastore C, Montella A, Lanzillo R, Kimura M, Jasperse B, Morra VB, Petraccia M, Pontillo G, Brunetti A, Cocozza S. *Neuroradiology.* 2024 Aug;66(8):1345-1352. doi: 10.1007/s00234-024-03310-5. Epub 2024 Feb 19. PMID: 38374410
75. [The influence of MOGAD on diagnosis of multiple sclerosis using MRI.](#) Geraldine R, Arrambide G, Banwell B, Rovira A, Cortese R, Lassmann H, Messina S, Rocca MA, Waters P, Chard D, Gasperini C, Hacohen Y, Mariano R, Paul F, DeLuca GC, Enzinger C, Kappos L, Leite MI, Sastre-Garriga J, Yousry T, Ciccarella O, Filippi M, Barkhof F, Palace J; MAGNIMS Study Group. *Nat Rev Neurol.* 2024 Oct;20(10):620-635. doi: 10.1038/s41582-024-01005-2. Epub 2024 Sep 3. PMID: 39227463 Review.
76. [The presence of attentional and interpretation biases in patients with severe MS-related fatigue.](#) de Gier M, Oosterman JM, Hughes AM, Moss-Morris R, Hirsch C, Beckerman H, de Groot V, Knoop H. *Br J Health Psychol.* 2024 Sep;29(3):731-745. doi: 10.1111/bjhp.12723. Epub 2024 Apr 4. PMID: 38575519
77. [The role of CD56 bright NK cells in neurodegenerative disorders.](#) Rodriguez-Mogeda, C., van Ansenwoude, C. M. J., van der Molen, L., Strijbis, E. M. M., Mebius, R. E. & de Vries, H. E., Dec 2024, In: *Journal of neuroinflammation.* 21, 1, p. 48 48. Research output: Contribution to journal › Review article › Academic › peer-review
78. [To halt disease progression rehabilitation in MS should start early: Yes.](#) Aarts J, de Groot V. *Mult Scler.* 2024 Nov;30(13):1592-1594. doi: 10.1177/13524585241289268. PMID: 39548692 Free PMC article. No abstract available.
79. [Towards a Unified Set of Diagnostic Criteria for Multiple Sclerosis.](#) Brownlee WJ, Vidal-Jordana A, Shatila M, Strijbis E, Schoof L, Killestein J, Barkhof F, Bollo L, Rovira A, Sastre-Garriga J, Tintore M, Rocca MA, Esposito F, Azzimonti M, Filippi M, Bodini B, Lazzarotto A, Stankoff B, Montalban X, Toosy AT, Thompson AJ, Ciccarella O; MAGNIMS Study Group. *Ann Neurol.* 2024 Nov 28. doi: 10.1002/ana.27145. Online ahead of print. PMID: 39605172

80. [Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: A retrospective analysis.](#) Calvi A, Mendelsohn Z, Hamed W, Chard D, Tur C, Stutters J, MacManus D, Kanber B, Wheeler-Kingshott CAMG, Barkhof F, Prados F. *Eur J Neurol.* 2024 Jan;31(1):e16092. doi: 10.1111/ene.16092. Epub 2023 Oct 12. PMID: 37823722 Free PMC article.
81. [Use of gadolinium-based contrast agents in multiple sclerosis: a review by the ESMRMB-GREC and ESNR Multiple Sclerosis Working Group.](#) Rovira À, Doniselli FM, Auger C, Haider L, Hodel J, Severino M, Wattjes MP, van der Molen AJ, Jasperse B, Mallio CA, Yousry T, Quattrocchi CC; ESMRMB-GREC Working Group and of the ESNR Multiple Sclerosis Working Group. *Eur Radiol.* 2024 Mar;34(3):1726-1735. doi: 10.1007/s00330-023-10151-y. Epub 2023 Sep 2. PMID: 37658891 Review.
82. [Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis.](#) Ciccarelli O, Barkhof F, Calabrese M, De Stefano N, Eshaghi A, Filippi M, Gasperini C, Granziera C, Kappos L, Rocca MA, Rovira À, Sastre-Garriga J, Sormani MP, Tur C, Toosy AT; as the MAGNIMS Study Group. *Neurology.* 2024 Jul 9;103(1):e209444. doi: 10.1212/WNL.0000000000209444. Epub 2024 Jun 18. PMID: 38889384 Free PMC article. Review.
83. [Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome.](#) Butzkueven H, Ponsonby AL, Stein MS, Lucas RM, Mason D, Broadley S, Kilpatrick T, Lechner-Scott J, Barnett M, Carroll W, Mitchell P, Hardy TA, Macdonell R, McCombe P, Lee A, Kalincik T, van der Walt A, Lynch C, Abernethy D, Willoughby E, Barkhof F, MacManus D, Clarke M, Andrew J, Morahan J, Zhu C, Dear K, Taylor BV; PREVANZ Investigators. *Brain.* 2024 Apr 4;147(4):1206-1215. doi: 10.1093/brain/awad409. PMID: 38085047 Free PMC article. Clinical Trial.